Adicet Bio, Inc. (ACET) News
Follow Adicet Bio, Inc. (ACET) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 14 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Adicet Bio Price Target Raised to $28.00/Share From $25.00 by Wedbush
Ratings actions from Benzinga: GMT) Adicet Bio Is Maintained at Outperform by WedbushRatings actions from Benzinga
NEWS | Sep 29, 2026, 12:28 PM UTC
L
Wedbush maintains Outperform rating on Adicet Bio, $28 price target
Wedbush maintained their Outperform rating on Adicet Bio's stock with a price target of $28.00.The price target implies an upside of 340.9% from the Sep 28 close of $6.35.Key takeaways from the analyst noteStrong Clinica
REGULATION | Sep 29, 2026, 12:17 PM UTC
L
Adicet Bio Is Maintained at Buy by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 02:37 PM UTC
L
HC Wainwright & Co. maintains Buy rating on Adicet Bio, $34 price target
HC Wainwright & Co. maintained their Buy rating on Adicet Bio's stock with a price target of $34.00.The price target implies an upside of 276.9% from the Sep 25 close of $9.02.Key takeaways from the analyst noteFavorable
EQUITY | Sep 28, 2026, 02:27 PM UTC
L
Adicet reports positive Phase 1 prula-cel data; 54% DORIS, 50% CRR at 12 months, favorable safety
Adicet reported positive Phase 1 prula-cel data showing 54% DORIS remission and 50% complete renal response at 12 months with a favorable safety profile.Key Highlights:Original SEC Filing: Adicet Bio, Inc. [ ACET ] - 8-K
REGULATION | Sep 28, 2026, 12:25 PM UTC
L
Adicet Bio, Inc. (ACET) Reports Positive SLE/LN Phase 1 Data, Plans Pivotal LN Study Start-Up in Q4 2026
Adicet Bio reported positive safety and efficacy from a Phase 1 study of prula-cel in SLE with or without lupus nephritis, and plans to initiate start-up activities for a single-arm pivotal LN study in Q4 2026 with compl
NEWS | Sep 28, 2026, 10:45 AM UTC
L
Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
Adicet Bio, Inc. (NASDAQ:ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid
NEWS | Sep 28, 2026, 10:45 AM UTC
L
Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid
NEWS | Sep 25, 2026, 08:00 PM UTC
L
Adicet Bio posts September 2026 investor presentation
Adicet Bio posted a September 2026 investor presentation highlighting prula-cel clinical progress and IND-cleared ADI-212 with near-term clinic timelines.
REGULATION | Sep 08, 2026, 08:24 PM UTC
L
Adicet Bio to join H.C. Wainwright fireside chat
Adicet Bio, Inc. (Nasdaq: ACET) announced CEO Chen Schor will participate in a fireside chat at H.C. Wainwright’s 28th Annual Global Investment Conference.
EQUITY | Sep 02, 2026, 08:00 PM UTC
L
Adicet Bio completes prula-cel last patient visit
Adicet Bio said the last patient visit for prula-cel is complete and topline SLE data is expected in September 2026. The company also said ADI-212 IND has cleared.
REGULATION | Sep 01, 2026, 11:03 AM UTC
L
Adicet Bio completes last patient visit for planned prula-cel analysis
Adicet Bio (ACET) said it has completed the last patient visit for the planned analysis of its prula-cel (formerly ADI-001) study in systemic lupus erythematosus with or without lupus nephritis, and provided a corporate
EQUITY | Sep 01, 2026, 11:00 AM UTC
L
Adicet Bio reports inducement grant under Nasdaq Rule 5635(c)(4)
Adicet Bio reported an inducement grant under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Aug 31, 2026, 09:39 PM UTC
M
Adicet Bio gets FDA clearance for Phase 1 prostate cancer trial
Adicet Bio announced FDA clearance for a Phase 1 trial of its prostate cancer treatment.
REGULATION | Aug 27, 2026, 08:58 PM UTC